Using Analytics to Maximize Copay Program Effectiveness

Click here to view the session

As manufacturers began to shift from pure product sampling strategies to more blended ones comprised of sampling, vouchers, and copays, the advantages generated were clearly evident: the entire cost of the product was no longer always being subsidized. As such, manufacturers were content to receive data on the numbers of redemptions, patients, and prescribers participating. However, as the copay industry has matured, these measures have become less and less adequate. Instead, pharmaceutical manufacturers are looking to analytics, with their rich sources of evidence, demonstrations of convincing payback, and sophisticated predictive models as requirements of their patient access suppliers. In this webcast, TrialCard provides an overview of the analytic data that we use to help our manufacturers to design the most effective campaigns and to assess their effectiveness.


Featured Speaker:
Paul LeVine, Vice President of Analytic Services, TrialCard


Sponsored by:

You must be a registered member of MMM to post a comment.
close

Next Article in Features


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.

Email Newsletters


Pharma continues to struggle with its image. Exhibit A is the public debate around the price of, and access to, new and innovative meds. As countless transformative technologies hit market, has industry done enough to anchor its permission to innovate? To provide a closer look at trends affecting trust over the past year, MM&M presents this e-book, "The 2015 Edelman Trust Barometer." Click here.